Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|December 19, 2025

BioPharm International Sponsored eBooks

  • BioPharm International Sponsored eBooks-12-19-25

Novel Delivery Approaches of Biopharmaceuticals 2025

Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.